TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Safety/Toxicity of subcutaneous injections
Endpoint domain: Adverse events/effects
Primary endpoint: long-term complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Heartburn-free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Steady-state Average Concentration (ssCavg) of Posaconazole on Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state Area Under the Concentration-time Curve (ssAUC0-24hr) of Posaconazole on Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state Maximum Concentration (ssCmax) of Posaconazole on Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deposition of sterile air depositions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Referrals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline in Decision conflict scale (DCS) at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline Decision conflict scale (DCS) at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percent of stones passed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to pass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Tolerated Dose (MTD) of entolimod
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of entolimod
Endpoint domain: Adverse events/effects
Primary endpoint: Stenosis postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in VAS Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sun Protection Behavior Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: local anesthetic dose in 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of peri-bronchial and blood circulating fibrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accurate understanding of genetic risk information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Adverse Events (AE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Success of Outcome evaluated by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of mature follicular count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Increase in the percentage of IMAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Achieving Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Viral Load at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Viral Load at 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median CD4 Cell Count Increase at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median CD4 Cell Count Increase at 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of C-X-C Chemokine Receptor 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Enrollment numbers per course
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Views per video
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of actively engaged students per course
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Lower leg muscle power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in content knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnostic accuracy of 18F-FLT PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal microbiota range-weighted richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentration of short-chain fatty acids in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in free hemoglobin plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post neonatal under-five all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: AUC of live vaccine virus shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Stride Time Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Subjects Achieving LDL-C Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacodynamics of ERT with pre-medication Zavesca
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average skin-to-skin time of the first surgical debridement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent Change in Fasting Serum Triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Video (VDO) loops visualization of lumbar plexus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pain measured with visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in perception of pain measured with an algometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Experiencing Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary Albumin Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of patients with successful desensitization procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month Progression-free Survival (6mPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Hospital free days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants With Revascularization of the Occluded Target Vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Device-related and Procedure-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Increment in 25(OH)vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delay of recurrence of schistosomiasis pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TST Induration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of proximal serrated polyp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of acceptance of contraception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of conversion to laparotomy or laparoscopy assisted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: IgG4 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hepatic steatosis regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioavailability of vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of residents prescribed osteoporosis medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of Hepatitis A Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: neuropsychological test scores (MCCB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MEG alpha oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence Rate of Dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 6 Month Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Columbia Suicide Severity Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of BUP/NLX With Raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participant samples indicating urine contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants Progression-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Achieving DAS28-CRP<=3.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Achieving DAS28-ESR<=3.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Absolute Relative Difference (MARD) calculations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of variants identified in sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of calcium content in carotid atheromatous plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under plasma concentration time curve (AUC last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DCE-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of unique active lesions per scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Health (dental examination)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chewing function I (examination with force gauge meter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance from the inferior orbital rim to the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in paternal mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Subjects in Disease Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Sexual Experience Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Relationship Satisfaction Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neurobehavioral score by NAPI at 40 weeks of corrected gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypercapnic Ventilatory Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Exercise Pulmonary Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Volume of brain with damages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PASI 75 Response After 12 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: IGA Mod 2011 0 or 1 Response After 12 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: incidence of duodenal stump leak
Endpoint domain: Adverse events/effects
Primary endpoint: Allergenicity of modified tree pollen allergoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With a Seroresponse (Pan-Ig ELISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary Iodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Salt Iodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Withhold of intracranial progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Emptying rate from the gastric tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gaze duration bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of white blood cell (WBC) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients achieving well-controlled asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fluoxetine concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Developed Post-ERCP Pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Total Opioid Administered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety and tolerability of the HIV CTL MEP vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Difference Between Early Morning and Evening Weights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive-ratio break point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peptidoglycan recognition protein-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in O2 output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haematology/biochemical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vaccine reactogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in social function
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Peri-implant inflammation of the soft tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Density of the peri-implant soft tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall average knee pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in CSF Aβ1-40 Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in CSF Aβ1-42 Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-anaesthesia care unit (PACU) length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence of iron overload
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of thyroid-stimulating hormone (TSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Self report general wellness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Stroke or Death
Endpoint domain: Mortality/survival
Primary endpoint: changes in respiratory muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in perception of dyspnea
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: changes in exercise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of knee extensors and knee flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response (RR) rate
Endpoint domain: Mortality/survival
Primary endpoint: 6 months survival in patients with microsatellite instability
Endpoint domain: Mortality/survival
Primary endpoint: Sustained Virologic Response (SVR) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative nalbuphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Steady state plasma concentrations of TMC125
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with a matching diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Physicians' Patients With Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Physicians' Patients Prescribed Guideline-recommended Antihypertensive Medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in total Functional Independence Measure (TFIM) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in FIM-cognitive subscore
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in FIM-motor subscore
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Migraine Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine Assessment by Anzola's Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-related Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Virological Response 12 Weeks Post-Treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in motor function of the affected extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathologic detection of pilonidal sinus disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of postoperative language deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Insulin/glucose ratio after overnight fast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin/glucose ratio after an oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of rupture
Endpoint domain: Adverse events/effects
Primary endpoint: rate of capsular contracture
Endpoint domain: Adverse events/effects
Primary endpoint: Fulfillment of Bath Ankylosing Spondylitis Disease Activity Index 50 Response (BASDAI50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Breast Implant Rupture
Endpoint domain: Adverse events/effects
Primary endpoint: Nursing Delirium Screening Scale (Nu-DESC) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of RO4995855 and its metabolite(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Width of the syndesmosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lickert scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Infusion Set Failure at the End of Day 6
Endpoint domain: Adverse events/effects
Primary endpoint: Cmin,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected Thrombolysis In Myocardial Infarction frame count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean IRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean DCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean DL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean upper esophageal sphincter mean resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean lower esophageal sphincter mean resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relative Potency Max Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative Potency QTcB Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score - sport (KOOS Sport)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area under the glucose infusion rate curve (AUCGIR) 12-30h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cosmesis of the lesion and surrounding skin
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning